1. The median follow-up period for health-related quality-of-life (HRQOL) outcomes analyses was...
Read More
1. Event-free survival and median overall survival were significantly longer in the combination...
Read More
1. This population-based cohort study demonstrated that there was a 20.7% reduction in cancer care...
Read More
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher...
Read More
Click to read this study in The Lancet Oncology.
Read More
1. At 10-year follow-up, patients with early-stage breast cancer who underwent mastectomy with...
Read More
1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a...
Read More
1. This single-centred, observational cohort study demonstrated that among patients with head and...
Read More
1. The median overall survival for pembrolizumab versus chemotherapy was not statistically...
Read More
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher...
Read More
1. Patients in the control group had higher mean health care utilization costs across the...
Read More
1. In this retrospective cohort study, 462 patients with locally advanced gastric cancer...
Read More
For a study, researchers sought to explore the hypothesis that neonatal hypoglycemia is related to...
Read More
For a study, researchers sought to investigate the effects of preventive dextrose gel on...
Read More
For a study, researchers sought to look at the relationship between (Left Atrial) LA function and...
Read More
Click to read this study in JAMA Oncology.
Read More
1. Carotuximab in tandem with pazopanib did not show improvement in progression-free survival or...
Read More
1. Adherence to the guidelines increased from 38% to 56% between Fall 2016 and 2019; and from 37%...
Read More
1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and...
Read More
1. In this study, patients who were obese or overweight had better survival compared to normal...
Read More
